Effect of probiotic vs placebo in Non Constipated Irritable Bowel Syndrome
- Conditions
- Health Condition 1: K580- Irritable bowel syndrome with diarrheaHealth Condition 2: K582- Mixed irritable bowel syndrome
- Registration Number
- CTRI/2020/07/026863
- Lead Sponsor
- Zydus Healthcare Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
1. Subjects in the age group of 18-65 years (both ages inclusive) with a positive diagnoses of non-constipated IBS ) diagnosed based on responses to the Enhanced Asian ROME 3 Questionnaire
2. Criteria fulfilled for the last 3 months with symptom onset at least 6 months before study.
3. Able to provide signed informed consent and be able to comply with study procedures
1.Subjects with Constipation Predominant IBS (IBS-C)
2.Subjects with history of major abdominal surgery, a history of inflammatory bowel disease or diverticular disease, celiac disease, structural abnormalities of the gastrointestinal tract other than oesophagitis or gastritis allergic diseases.
3.Other organic or major psychiatric disorders such as schizophrenia manic depressive conditions as assessed by medical history, appropriate consultations and laboratory tests. 4.Faecal occult blood test positive
5.Pregnant or Lactating mothers
6.Any other medical condition in the opinion of the investigator rendering the subject ineligible to participate.
7.Use of antibiotics or probiotics in the three weeks preceding study start.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method